Cargando…

Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment

BACKGROUND: Histological transformation of advanced non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is one of the mechanisms of resistance to third-generation tyrosine kinase inhibitors (TKIs), such as osimertinib. This acquired TKI resistance is linked to the high degree of tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vendrell, Julie A., Quantin, Xavier, Serre, Isabelle, Solassol, Jérôme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750569/ https://www.ncbi.nlm.nih.gov/pubmed/33414847 http://dx.doi.org/10.1177/1758835920974192

Ejemplares similares

EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
por: Vendrell, Julie A., et al.
Publicado: (2021)

Case report: Liquid biopsy, the sooner the better?
por: Thomas, Quentin Dominique, et al.
Publicado: (2022)

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
por: Solassol, Isabelle, et al.
Publicado: (2019)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2021)

Transformation from lung adenocarcinoma to combined small cell carcinoma in pleural effusion after treatment with osimertinib
por: Frankel, Diane, et al.
Publicado: (2022)

Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy
por: Kallergi, Galatea, et al.
Publicado: (2022)

Assessment of Anti-tumor Efficacy of Osimertinib in Non–Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
por: Kim, Yeon Joo, et al.
Publicado: (2022)

Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-Analysis
por: Mlika, Mona, et al.
Publicado: (2018)

Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report
por: Taniguchi, Yuri, et al.
Publicado: (2018)

Determination of the Optimal Bacterial DNA Extraction Method to Explore the Urinary Microbiota
por: Vendrell, Julie A., et al.
Publicado: (2022)

Challenges in using liquid biopsies for gene expression profiling
por: Porras, Tania B., et al.
Publicado: (2018)

Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management
por: Vendrell, Julie A., et al.
Publicado: (2017)

Liquid biopsy epigenomic profiling for cancer subtyping
por: Baca, Sylvan C., et al.
Publicado: (2023)

High-throughput detection of clinically targetable alterations using next-generation sequencing
por: Vendrell, Julie A., et al.
Publicado: (2017)

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches
por: Vendrell, Julie A., et al.
Publicado: (2017)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Liquid Biopsy in Non-Small Cell Lung Cancer
por: Molina-Vila, Miguel A., et al.
Publicado: (2016)

Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens
por: Frouin, Eric, et al.
Publicado: (2016)

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma
por: Blateau, Pauline, et al.
Publicado: (2020)

ifCNV: A novel isolation-forest-based package to detect copy-number variations from various targeted NGS datasets
por: Cabello-Aguilar, Simon, et al.
Publicado: (2022)

Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine
por: Luchini, Claudio, et al.
Publicado: (2019)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib
por: Ren, Xiaohui, et al.
Publicado: (2020)

Incidentally Detected Small Cell Transformation in a Patient With Resected Oligometastatic EGFR-Mutated Lung Cancer Treated With Osimertinib
por: Teixeira, Carlos Henrique A., et al.
Publicado: (2020)

Generation and Characterization of a New Preclinical Mouse Model of EGFR-Driven Lung Cancer with MET-Induced Osimertinib Resistance
por: Mancini, Maicol, et al.
Publicado: (2021)

P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS
por: Moia, R., et al.
Publicado: (2022)

Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer?
por: Calabrese, Fiorella, et al.
Publicado: (2019)

Liquid Biopsy in Neurological Diseases
por: Malhotra, Sunny, et al.
Publicado: (2023)

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
por: Ezeife, Doreen A., et al.
Publicado: (2022)

Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities
por: Liebs, Sandra, et al.
Publicado: (2021)

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer
por: Sivakumar, Smruthy, et al.
Publicado: (2022)

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
por: Urbanska, Edyta M., et al.
Publicado: (2022)

Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface
por: Belluomini, L., et al.
Publicado: (2021)

Liquid biopsy reveals collateral tissue damage in cancer
por: Lubotzky, Asael, et al.
Publicado: (2022)

Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy
por: Gilson, Pauline, et al.
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Analysis of solid tumor mutation profiles in liquid biopsy
por: Balaji, Sai A., et al.
Publicado: (2018)

Evaluating liquid biopsies for methylomic profiling of prostate cancer
por: Silva, Romina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8mg0bg52se8706mv3ds1va2fvv